Archive for the ‘Int’l Practice and Policy’ Category

NOVARTIS A.G. v. UOI – What is Novelty in Indian Courts?

Monday, April 8th, 2013

Can everything old be made new again?  Lots has been written about the Indian Supreme Court rejecting a patent application claiming a crystal modification of imatinib mesylate (Gleevec), which is used to treat CML.  Novartis’ attempt to “evergreen” Gleevec with this patent – which will not expire until May of 2019 – failed in India.  I think the below linked newsletter account of the rationale of the court, from Lakshmikumaran & Sridharan, a leading Indian law firm, is the best I have encountered so far, so I won’t try to summarize it.

IPR Amicus Newsletter

 

Deposit of Biological Material – Impact on Validity of Priority Claim

Friday, March 1st, 2013

Please find linked below a guest post from Dr. Stefan Danner dealing with a new decision of the EPO Technical Boards of Appeal concerning the deposit of biological material.

Biotech IP Newsletter

 

“Global Dossier” May Lead to IP5 “One Portal” Filings

Friday, August 3rd, 2012

As reported in Director Kappos’ blog, progress is being made in harmonizing the patent filing process in the IP5 countries. This may be as big an advance in patent law as the EPO – including our hope for a single EU patent. Wish everyone, “Full faith and credit.”

Major Changes to IP Law in Australia Enacted

Thursday, April 19th, 2012

This guest post by Tom Gumley, PhD, a partner in the well-known Freehills Patent and Trademark firm provides a lengthy guide to the changes wrought by Australia’s new patent law, that was enacted on April 15, 2012. The law brings Australia closer to the US in many of its legal standards and, like the AIA, goes into effect at various times in the future.

*****

We are pleased to provide Freehills’ guide to Australia’s new patent law [available at the end of this post] that was signed into law on April 15, 2012.

This new law will have far-reaching consequences for those seeking and enforcing patent rights in Australia, and ultimately will establish a class of new Act patents to which higher validity standards required by the new law will apply, and old Act patents to which relatively lower validity standards established by the old law will apply.

There will also be important consequences regarding exemption from infringement for patentees and alleged infringers with the codification of experimental use provisions, and a broadening of old law exemptions to cover acts done for seeking regulatory approval of any product for which approval is required for marketing.

If you or your clients have business interests in Australia, it is very important that you come to an understanding of the new law sooner rather than later, as in many instances, the opportunities to be had and the risks to be mitigated under the new law will require you to take relevant action now.

Given the complexity of the new law, our commentary is necessarily of a general nature and we strongly advise you to contact us should you require professional advice on any particular issue.

Regards,

Tom Gumley PhD
Partner
Freehills Patent and Trade Mark Attorneys

Guide to Australia’s new patent law